$3.7m for Advanance's "direct detection" molecular Dx tech:
This article was originally published in Clinica
Executive Summary
Canadian start-up Adnavance Technologies is pushing ahead with development of its metallised-DNA (M-DNA) technology using the $3.7m it raised in a series B financing. The round was led by the Working Opportunity Fund, which is managed by GrowthWorks Capital, JovInvestment Management and Business Development Bank of Canada. Vancouver, British Columbia-based Adnavance is developing a direct detection molecular diagnostic technology, which eliminates the need for amplification of the DNA/RNA in the patient's sample. This allows hospitals and smaller independent labs to conduct their own testing, said Adnavance. The company will initially develop an M-DNA test for MRSA, which is expected to hit the market in 2010. In conjunction with the financing, Adnavance also announced the appointment of Randy White as CEO. Dr White's molecular diagnostics experience includes serving as CEO for Xenomics and Nanogen.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.